MS
ALXN

Maven Securities’s Alexion Pharmaceuticals ALXN Stock Holding History

Maven Securities’s Portfolio ALXN Stock Details ALXN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-62,000
Closed -$11.4M – 1452
2021
Q2 		$11.4M Sell
62,000
-87,329
-58% -$15M 0.46% 32
2021
Q1 		$23M Buy
149,329
+47,919
+47% +$7.41M 1.03% 11
2020
Q4 		$15.8M Buy
+101,410
New +$13M 1.57% 4
2017
Q1 		– Sell
-177
Closed -$22K – 67
2016
Q4 		$22K Buy
+177
New +$21.7K 0.02% 40

Other funds holding ALXN

BCI
Brinker Capital Investments Berwyn, Pennsylvania $13.1B AUM 28.37% 1-Year Est. Return
NICM
Neo Ivy Capital Management New York $434M AUM 44.19% 1-Year Est. Return
TAIM
TD Ameritrade Investment Management Omaha, Nebraska $9.4B AUM 7.2% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $521B AUM 51.41% 1-Year Est. Return
RG
Retirement Group San Diego, California $279M AUM 22.21% 1-Year Est. Return
CFO
CVA Family Office Denver, Colorado $1.1B AUM 26.6% 1-Year Est. Return
MAM
Meeder Asset Management Dublin, Ohio $1.96B AUM 48.96% 1-Year Est. Return

Maven Securities's ALXN Position: Q3 2021 in Review

Maven Securities sold out of Alexion Pharmaceuticals (ALXN) in Q3 2021, closing a stake of 62,000 shares — an estimated $11.4M sold.

Maven Securities first reported a position in ALXN in Q4 2016 and held it in 4 quarters. The position peaked at $23M in Q1 2021. 7 funds tracked by Wall St. Rank hold ALXN as of Q3 2021.

  • Maven Securities reported no remaining Alexion Pharmaceuticals position as of Q3 2021 after selling out during the quarter.
  • Maven Securities sold 62,000 Alexion Pharmaceuticals shares in Q3 2021, an estimated $11.4M.
  • Maven Securities first reported a position in Alexion Pharmaceuticals in Q4 2016 and held it in 4 quarters.
  • Maven Securities's Alexion Pharmaceuticals position peaked at $23M in Q1 2021.
  • 7 funds tracked by Wall St. Rank held Alexion Pharmaceuticals as of Q3 2021.

Based on Maven Securities's 13F filing for Q3 2021, filed 15 Nov 2021.